跳至主要内容
临床试验/NCT04005586
NCT04005586已完成不适用

A Prospective Controlled Multi-Center Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)

RxSight, Inc.4 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2019年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
RxSight, Inc.
入组人数
25
试验地点
4
主要终点
Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups

研究概览

简要总结

The primary objective of this study is to evaluate the safety and effectiveness of performing 0.50 D cylinder correction on the RxSight Light Adjustable Lens (LAL) in patients who have undergone implantation with the FDA approved, commercially available LAL.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • A study eye implanted with the commercially approved LAL that has not undergone any previous LDD treatments
  • A study eye with manifest refraction cylinder of 0.50 D measured by two independent examiners at the Adjustment #1 visit prior to the first light adjustment treatment.
  • Sign a written Informed Consent form and be willing to receive light treatment for their 0.50 D of cylinder.
  • Between the ages of 40 and 80 inclusive on the day the informed consent form is signed.
  • Good vision in the fellow eye with best corrected distance visual acuity (BCDVA) 20/40 or better.
  • Willing and able to comply with the requirements for study specific procedures and visits

排除标准

  • Pre-existing macular disease in the study eye.
  • History of uveitis in the study eye.
  • Has undergone previous corneal or intraocular surgery in the study eye, except for the cataract surgery and eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus.
  • Subjects taking systemic medication that may increase sensitivity to UV light.
  • Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.
  • History of ocular herpes simplex virus in the study eye.
  • Subject who has participated within another ophthalmic clinical trial within the last 3 months.
  • Sutures used at the time of surgery to close the incision wound in the study eye

结局指标

主要结局

Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups

时间窗: Post Op Month 3

Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups

时间窗: Post Op Month 3

次要结局

未报告次要终点

研究者

发起方
RxSight, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验